Navigation Links
UC Davis bench-to-bedside research: Promising treatment in clinical trials
Date:3/26/2009

occur together and a new class of drugs that addresses both is very attractive."

Cardiologist and cell biologist Nipavan Chiamvimonvat of the UC Davis Health System and a longtime collaborator with Hammock, said many diseases tend to occur together in vascular biology. "So, a compound that addresses heart failure, as we have shown, combined with the reduction of blood pressure, inflammation and diabetes is very attractive."

The Phase IIa clinical trial is a double-blind, placebo-controlled study. Officials will enroll a total of 150 patients with impaired glucose tolerance, mild obesity and mild to moderate hypertension.

Each patient will receive 28 days of treatment. The AR9281 enzyme inhibitor will be studied for safety, tolerability, reduction of blood pressure and various measures of glucose and lipid metabolism. Results are expected the first quarter of 2010.

The winding, twisting path that took Hammock from his lab, to collaborative research with other UC Davis scientists, to his founding of a $50 million-investment biotechnology company, to clinical trials proved as steep as the mountains he climbs.

Tracing the events that led to the discovery of the enzyme, Hammock recalled doing research at UC Berkeley four decades ago with then-colleague Sarjeet Gill. Gill discovered the enzyme in mammals. Shortly after Hammock found the novel enzyme in insects.

"Both of us have been chipping away at this problem ever since," Hammock said. "By 1975 we were convinced that this was a therapeutic target but no one else was. When we finally found potent inhibitors for the enzyme that worked in whole animals, we had a tool to demonstrate that this was a promising therapeutic target."

Hammock was initially interested in regulating the development of insect larvae. With the discovery of the enzyme inhibitor, however, he switched part of his research from "pest control to pain control."

At the onset,
'/>"/>

Contact: Kathy Keatley Garvey
kegarvey@ucdavis.edu
530-754-6894
University of California - Davis
Source:Eurekalert  

Page: 1 2 3 4 5

Related biology news :

1. UC Davis research shows that newly discovered drug reduces heart enlargement
2. UC Davis researchers find molecule that targets brain tumors
3. UC Davis discovery offers hope for treating kidney cancer
4. UC Davis team refines cancer treatments to reduce potential nerve damage
5. UC Davis researchers exploring gene therapy to fight AIDS
6. UC Davis researchers discover Achilles heel in pancreatic cancer
7. UC Davis researchers discover a key to aggressive breast cancer
8. UC Davis chemical ecologist wins major award
9. UC Davis researchers discover new drug target for inflammatory disease
10. UC Davis researchers define characteristics, treatment options for XXYY syndrome
11. UC Davis researcher leads climate-change discovery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UC Davis bench-to-bedside research: Promising treatment in clinical trials
(Date:9/23/2014)... Research and Markets  has announced the ... Opportunities, 2019" report to their offering. ... security and protection in private as well as government ... government is focusing on using biometric systems to store ... IDs that are of crucial importance to the country. ...
(Date:9/23/2014)... Newest Market IPO,s and ... for significant investor attention with news concerning shareholder updates and ... are: NXT-ID, Inc. (NASDAQ: NXTD ), Alibaba Group ... MBLY ), GoPro, Inc. (NASDAQ: GPRO ... Inc. (NASDAQ: NXTD ) recently completed an essential ...
(Date:9/23/2014)... parasitic DNA fragments called "jumping genes" that insert themselves ... And that phenomenon can result in age-related diseases such ... now report that the "jumping genes" in mice become ... stops keeping them in check in order to take ... today in Nature Communications , Professor of Biology ...
Breaking Biology News(10 mins):India Biometrics Market Forecast and Opportunities, 2019 2India Biometrics Market Forecast and Opportunities, 2019 3Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 2Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 3Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 4Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 5Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 6Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 7A multi-function protein is key to stopping genomic parasites from 'jumping' 2
... therapies similar to those used for HIV patients may be the ... the University of Leeds. A study of a protein called ... the protein between virus strains - known as genotypes - ... function. The p7 protein assists the spread of HCV ...
... U.S. Department of Energy Joint Genome Institute (DOE JGI) ... (Glycine max) genetic code, making it widely available to ... one of the world,s most valuable plant commodities. ... world,s edible protein, but also is an emerging feedstock ...
... DECEMBER 8, 2008 Animal feeding operations are an ... and carbon dioxideknown greenhouse gases. Recent inventories suggest ... global methane emissions. As a consequence, greenhouse gas ... the development and sustainability of animal production and ...
Cached Biology News:Leeds research points to new therapy for hepatitis C treatment 2DOE Joint Genome Institute completes soybean genome 2DOE Joint Genome Institute completes soybean genome 3Oil spray reduces greenhouse gas emissions from pig finishing barns 2
(Date:9/23/2014)... September 23, 2014 Dr. Williams says, ... book on healthcare offers a three phase process that ... healthcare delivery system that would go far beyond anything ... regarding the delivery of healthcare.” , “Every effort to ... failed to provide discernable progress throughout that system because ...
(Date:9/22/2014)... were treated with a statin in the hospital after ... to survive than those who were not, according to ... This study was conducted by the same researchers who ... improve survival in victims of ischemic stroke., Ischemic stroke ... blood vessel that blocks blood from reaching areas of ...
(Date:9/22/2014)... LEGO-like components developed by researchers at the USC ... to build a 3-D microfluidic system quickly and ... hand. , Microfluidic systems are used in ... precisely manipulate small volumes of fluids for use ... pathogen detection, clinical diagnostic testing, and synthetic chemistry. ...
(Date:9/22/2014)... developed a unique nanoscale device that for the ... discovery could have major implications for creating faster ... communication. , The research paper by University of ... Li and his graduate student Huan Li has ... October issue of Nature Nanotechnology . , ...
Breaking Biology Technology:Dr. Ira Williams Offers the Healthcare Solution Necessary for Patient Safety Improvement 2Statin use during hospitalization for hemorrhagic stroke associated with improved survival 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 3Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 5Engineers show light can play seesaw at the nanoscale 2
... , , , ... (Medical College), a private medical school with more than 1,100 physicians, ... (SRM) solution to track, manage and report adverse and near-miss events, ... Event Manager (EM) and Claims Manager (CM) modules, part of the ...
... ... Room To Share Due Diligence Documents , ... Los Gatos, CA (PRWEB) September 16, 2009 -- Pandesa ... a number of pharmaceutical, biopharmaceutical and biotech research and development companies worldwide, to securely ...
... AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: ... endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, ... licensee for perifosine in the North American market, has ... Food and Drug Administration (FDA) for the treatment of ...
Cached Biology Technology:The Medical College of Wisconsin Adopts Quantros Event Manager(TM) and Claims Manager(TM) for Comprehensive Malpractice Litigation Management 2Pandesa ShareVault Enables Secure, Real-time Due Diligence for Biopharmaceutical Partnering 2Pandesa ShareVault Enables Secure, Real-time Due Diligence for Biopharmaceutical Partnering 3AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 2AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 3
Defender against cell death 1...
Request Info...
... Hypothetical protein FLJ20644, likely ortholog of ... Protein Accession #: NP_060387.1 gi ... Definition: chromosome 14 open reading frame ... gene g4-1 [Homo sapiens] Locus ...
1/4" to 1/8" Adapter for Reflectance Probe Holder...
Biology Products: